Inhibrx reported that its monoclonal antibody ozekibart hit the primary endpoint in a registrational phase II trial for advanced or metastatic unresectable chondrosarcoma, producing significant and clinically meaningful improvements in median progression‑free survival. The topline data prompted management to target a biologics license application submission in H2 2026. The result addresses an orphan indication with few therapeutic options and drove a sharp share re‑rating. Inhibrx said it will collate full datasets for regulatory discussions and highlighted the potential for accelerated pathways given the rarity and unmet need in the disease.